The story
How Adcendo became Adcendo
Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet. The scientific founders, Niels Behrendt, Lars Engelholm and Christoffer Nielsen from The Finsen Laboratory, had just recently published proof-of-concept for uPARAP-directed ADCs, where a first-generation, anti-uPARAP ADC was shown to effectively mediate a curative outcome in a CDX model. Ensuring that these findings were investigated further by creating a spin-out company for this purpose, was a natural next step
In mid-2019, Adcendo was accepted into BioInnovation Institute (BII)’s Creation House Program (www.bii.dk). This allowed us to establish a small but highly dedicated team, accelerate our pre-clinical research activities, and further refine and deepen the proof-of-concept data for our uPARAP ADC program
In early 2021, Adcendo closed a series A financing round of 51m EUR in April 2021, one of the largest series A investments in Danish biotech to date
Since then, our company has established itself at the Copenhagen Bio Science Park (COBIS), where we continue to build the company, have established an internationally experienced and highly profiled leadership team, and a skilled, dedicated and continuously growing group of scientific employees
We are driven by making a meaningful difference for cancer patients in need based on innovation and passion for science
